16,687 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Oxford Asset Management LLP

Oxford Asset Management LLP purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,687 shares of the company's stock, valued at approximately $730,000.

Several other institutional investors have also recently made changes to their positions in the stock. Barclays PLC raised its stake in Revolution Medicines by 187.1% during the 3rd quarter. Barclays PLC now owns 294,664 shares of the company's stock worth $13,362,000 after acquiring an additional 192,021 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Revolution Medicines in the third quarter worth approximately $801,000. Lord Abbett & CO. LLC bought a new position in shares of Revolution Medicines in the third quarter worth approximately $83,082,000. Everence Capital Management Inc. bought a new position in shares of Revolution Medicines in the fourth quarter worth approximately $203,000. Finally, Avanza Fonder AB bought a new position in shares of Revolution Medicines in the fourth quarter worth approximately $173,000. Institutional investors own 94.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $59.00 price target on shares of Revolution Medicines in a research report on Tuesday, April 8th. HC Wainwright upped their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Stifel Nicolaus dropped their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Wedbush restated an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a research report on Monday. Finally, UBS Group upped their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $66.67.

Insider Activity

In related news, CFO Jack Anders sold 1,864 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares of the company's stock, valued at $4,489,834.24. This trade represents a 1.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mark A. Goldsmith sold 11,738 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now directly owns 441,564 shares in the company, valued at $17,238,658.56. This represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,660 shares of company stock valued at $650,406. 8.00% of the stock is currently owned by company insiders.

Revolution Medicines Stock Up 7.0 %

Revolution Medicines stock traded up $2.70 during mid-day trading on Monday, reaching $41.47. 2,872,304 shares of the company's stock traded hands, compared to its average volume of 1,437,485. The company has a market cap of $7.71 billion, a price-to-earnings ratio of -11.55 and a beta of 1.37. The stock has a 50 day moving average of $37.42 and a two-hundred day moving average of $43.95. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). As a group, sell-side analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.